These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 38018328)

  • 41. Hepatitis C prevalence and cascade of care among patients in the decentralised opioid agonist therapy programme of the canton of St Gallen, Switzerland: a cross-sectional study.
    Wissel K; Vernazza P; Kuster S; Hensel-Koch K; Bregenzer A
    Swiss Med Wkly; 2024 Feb; 154():3352. PubMed ID: 38579293
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study.
    Valerio H; Alavi M; Conway A; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Murray C; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Stevens A; Prain B; Hayllar J; Reid D; Montebello M; Wade A; Christmass M; Cock V; Dore GJ; Grebely J;
    Int J Drug Policy; 2022 Jul; 105():103706. PubMed ID: 35533635
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Integrated Care for the Use of Direct-acting Antivirals in Patients With Chronic Hepatitis C and Substance Use Disorder.
    Trabut JB; Barrault C; Charlot H; Carmona D; Bourdel A; Benslimane M; François M; Kini-Matondo W; Causse R; Roudot-Thoraval F; Hézode C
    J Addict Med; 2018; 12(5):346-352. PubMed ID: 29702515
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact.
    Martin NK; Foster GR; Vilar J; Ryder S; Cramp ME; Gordon F; Dillon JF; Craine N; Busse H; Clements A; Hutchinson SJ; Ustianowski A; Ramsay M; Goldberg DJ; Irving W; Hope V; De Angelis D; Lyons M; Vickerman P; Hickman M
    J Viral Hepat; 2015 Apr; 22(4):399-408. PubMed ID: 25288193
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High HCV cure rates among people who inject drugs and have suboptimal adherence: A patient-centered approach to HCV models of care.
    Norton BL; Akiyama MJ; Arnsten JH; Agyemang L; Heo M; Litwin AH
    Int J Drug Policy; 2021 Jul; 93():103135. PubMed ID: 33667826
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of Direct-acting Antivirals for Chronic Hepatitis C Virus Infection in People Who Inject Drugs or Receive Opioid Substitution Therapy: A Systematic Review and Meta-analysis.
    Graf C; Mücke MM; Dultz G; Peiffer KH; Kubesch A; Ingiliz P; Zeuzem S; Herrmann E; Vermehren J
    Clin Infect Dis; 2020 May; 70(11):2355-2365. PubMed ID: 31513710
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hepatitis C Virus Direct-Acting Antiviral Treatment Adherence Patterns and Sustained Viral Response Among People Who Inject Drugs Treated in Opioid Agonist Therapy Programs.
    Heo M; Pericot-Valverde I; Rennert L; Akiyama MJ; Norton BL; Gormley M; Agyemang L; Arnsten JH; Litwin AH
    Clin Infect Dis; 2021 Dec; 73(11):2093-2100. PubMed ID: 33876230
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Investigating rates and risk factors for hepatitis C virus reinfection in people receiving antiviral treatment in England.
    Hibbert M; Simmons R; Harris H; Desai M; Sabin CA; Mandal S
    J Viral Hepat; 2023 Aug; 30(8):646-655. PubMed ID: 36929670
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Outcomes of Treatment for Hepatitis C in Primary Care, Compared to Hospital-based Care: A Randomized, Controlled Trial in People Who Inject Drugs.
    Wade AJ; Doyle JS; Gane E; Stedman C; Draper B; Iser D; Roberts SK; Kemp W; Petrie D; Scott N; Higgs P; Agius PA; Roney J; Stothers L; Thompson AJ; Hellard ME
    Clin Infect Dis; 2020 Apr; 70(9):1900-1906. PubMed ID: 31233117
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject Drugs.
    Cunningham EB; Hajarizadeh B; Amin J; Hellard M; Bruneau J; Feld JJ; Cooper C; Powis J; Litwin AH; Marks P; Dalgard O; Conway B; Moriggia A; Stedman C; Read P; Bruggmann P; Lacombe K; Dunlop A; Applegate TL; Matthews GV; Fraser C; Dore GJ; Grebely J
    Clin Infect Dis; 2021 Apr; 72(8):1392-1400. PubMed ID: 32166305
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.
    Grebely J; Dalgard O; Conway B; Cunningham EB; Bruggmann P; Hajarizadeh B; Amin J; Bruneau J; Hellard M; Litwin AH; Marks P; Quiene S; Siriragavan S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop A; Matthews GV; Powis J; Shaw D; Thurnheer MC; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Dillon JF; Read P; Gane E; Dore GJ;
    Lancet Gastroenterol Hepatol; 2018 Mar; 3(3):153-161. PubMed ID: 29310928
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High Rate of Hepatitis C Virus Reinfection Among Recently Injecting Drug Users: Results From the TraP Hep C Program-A Prospective Nationwide, Population-Based Study.
    Johannesson JM; Fridriksdottir RH; Löve TJ; Runarsdottir V; Hansdóttir I; Löve A; Thordardottir M; Hernandez UB; Olafsson S; Gottfredsson M;
    Clin Infect Dis; 2022 Nov; 75(10):1732-1739. PubMed ID: 35438144
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice?
    Christensen S; Buggisch P; Mauss S; Böker KHW; Schott E; Klinker H; Zimmermann T; Weber B; Reimer J; Serfert Y; Wedemeyer H
    Addiction; 2018 May; 113(5):868-882. PubMed ID: 29359361
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Community-Based Assessment and Treatment of Hepatitis C Virus-Related Liver Disease, Injecting Drug and Alcohol Use Amongst People Who Are Homeless: A Systematic Review and Meta-Analysis.
    Hashim A; Macken L; Jones A; McGeer M; Aithal G; Verma S
    Int J Drug Policy; 2021 Oct; 96():103342. PubMed ID: 34210551
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: real-world data.
    Palmateer NE; McAuley A; Dillon JF; McDonald S; Yeung A; Smith S; Barclay S; Hayes P; Shepherd SJ; Gunson RN; Goldberg DJ; Hickman M; Hutchinson SJ
    Addiction; 2021 Oct; 116(10):2893-2907. PubMed ID: 33651446
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Overreporting of adherence to hepatitis C direct-acting antiviral therapy and sustained virologic response among people who inject drugs in the HERO study.
    Lopes SS; Pericot-Valverde I; Lum PJ; Taylor LE; Mehta SH; Tsui JI; Feinberg J; Kim AY; Norton BL; Page K; Murray-Krezan C; Anderson J; Karasz A; Arnsten J; Moschella P; Heo M; Litwin AH
    BMC Infect Dis; 2024 Feb; 24(1):251. PubMed ID: 38395747
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.
    Radley A; de Bruin M; Inglis SK; Donnan PT; Hapca A; Barclay ST; Fraser A; Dillon JF
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):809-818. PubMed ID: 32526210
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hepatitis C treatment outcomes among patients treated in co-located primary care and addiction treatment settings.
    Ngo BV; James JR; Blalock KL; Jackson SL; Chew LD; Tsui JI
    J Subst Abuse Treat; 2021 Dec; 131():108438. PubMed ID: 34098298
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada.
    Saeed S; Strumpf EC; Moodie EE; Young J; Nitulescu R; Cox J; Wong A; Walmsely S; Cooper C; Vachon ML; Martel-Laferriere V; Hull M; Conway B; Klein MB;
    J Int AIDS Soc; 2017 Nov; 20(3):. PubMed ID: 29116684
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Changes in alcohol use during hepatitis C treatment in persons who inject drugs.
    Martin M; Roth PJ; Niu J; Pericot-Valverde I; Heo M; Padi A; Norton BL; Akiyama MJ; Litwin AH
    J Viral Hepat; 2022 Nov; 29(11):1004-1014. PubMed ID: 35997620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.